AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections
04 janv. 2021 07h00 HE
|
AzurRx BioPharma, Inc.
Agreement expands AzurRx’s pipeline of targeted, non-systemic GI therapies Clinical trials to initiate in 1H’21, with potential for expedited FDA 505(b)(2) pathway for IND-approved COVID-19 and...